Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion.

[1]  Y. Byun,et al.  Intestinal transport mechanism and in vivo anticancer efficacy of a solid oral formulation incorporating an ion-pairing complex of pemetrexed with deoxycholic acid derivative , 2019, International journal of nanomedicine.

[2]  Y. Byun,et al.  Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy , 2019, Pharmaceutics.

[3]  L. Sequist,et al.  24‐Month Overall Survival from KEYNOTE‐021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First‐Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  Q. Wang,et al.  Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies. , 2018, Cancer letters.

[5]  N. Pavlović,et al.  Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles , 2018, Front. Pharmacol..

[6]  T. Webster,et al.  Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends , 2018, International journal of nanomedicine.

[7]  Y. Byun,et al.  Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect , 2018, International journal of nanomedicine.

[8]  M. Oliveira,et al.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion , 2018, Front. Immunol..

[9]  Ming-Tsang Wu,et al.  Nanoemulsion as a strategy for improving the oral bioavailability and anti-inflammatory activity of andrographolide , 2018, International journal of nanomedicine.

[10]  Haotian Zhang,et al.  Enhanced oral absorption and anticancer efficacy of cabazitaxel by overcoming intestinal mucus and epithelium barriers using surface polyethylene oxide (PEO) decorated positively charged polymer‐lipid hybrid nanoparticles , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Yao Jin,et al.  Improved intestinal absorption of paclitaxel by mixed micelles self-assembled from vitamin E succinate-based amphiphilic polymers and their transcellular transport mechanism and intracellular trafficking routes , 2018, Drug delivery.

[12]  R. Ferris,et al.  PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. , 2017, Cancer research.

[13]  Zhipeng Chen,et al.  Improving intestinal absorption and oral bioavailability of curcumin via taurocholic acid-modified nanostructured lipid carriers , 2017, International journal of nanomedicine.

[14]  I. Kareva.  A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells , 2017, International journal of molecular sciences.

[15]  B. Sarmento,et al.  Strategies for the enhanced intracellular delivery of nanomaterials , 2017, Drug Discovery Today.

[16]  Yu-Li Chen,et al.  Metronomic chemotherapy and immunotherapy in cancer treatment. , 2017, Cancer letters.

[17]  I. Frazer,et al.  Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity , 2017, Cell Death & Disease.

[18]  J. Urbina,et al.  Ravuconazole self-emulsifying delivery system: in vitro activity against Trypanosoma cruzi amastigotes and in vivo toxicity , 2017, International journal of nanomedicine.

[19]  C. Luceri,et al.  Nanoemulsion for improving solubility and permeability of Vitex agnus-castus extract: formulation and in vitro evaluation using PAMPA and Caco-2 approaches , 2017, Drug delivery.

[20]  Sang-Woon Choi,et al.  Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation , 2016, International journal of nanomedicine.

[21]  M. Colleoni,et al.  Clinical overview of metronomic chemotherapy in breast cancer , 2015, Nature Reviews Clinical Oncology.

[22]  E. Moghimipour,et al.  Absorption-Enhancing Effects of Bile Salts , 2015, Molecules.

[23]  S. Ibrić,et al.  Influence of Solid Drug Delivery System Formulation on Poorly Water-Soluble Drug Dissolution and Permeability , 2015, Molecules.

[24]  P. Dawson,et al.  Intestinal transport and metabolism of bile acids , 2015, Journal of Lipid Research.

[25]  B. Zhu,et al.  T-cell exhaustion in the tumor microenvironment , 2015, Cell Death and Disease.

[26]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[27]  Smita Raghuvanshi,et al.  Oral Bioavailability: Issues and Solutions via Nanoformulations , 2015, Clinical Pharmacokinetics.

[28]  T. Srichana,et al.  Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation. , 2014, International journal of pharmaceutics.

[29]  R. Holma,et al.  Deoxycholic acid induced changes in electrophysiological parameters and macromolecular permeability in murine small intestine with and without functional enteric nervous system plexuses , 2014, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[30]  K. Schalper.  PD-L1 expression and tumor-infiltrating lymphocytes , 2014, Oncoimmunology.

[31]  Mandip Singh,et al.  Approaches to Improve the Oral Bioavailability and Effects of Novel Anticancer Drugs Berberine and Betulinic Acid , 2014, PloS one.

[32]  Shweta Gupta,et al.  Formulation Strategies to Improve the Bioavailability of Poorly Absorbed Drugs with Special Emphasis on Self-Emulsifying Systems , 2013, ISRN pharmaceutics.

[33]  C. Figdor,et al.  Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go , 2013, Front. Immunol..

[34]  Qiang Zhang,et al.  The transport mechanisms of polymer nanoparticles in Caco-2 epithelial cells. , 2013, Biomaterials.

[35]  S. Ferrone,et al.  Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death , 2013, Journal of Immunotherapy for Cancer.

[36]  J. Chiang.  Bile acid metabolism and signaling. , 2013, Comprehensive Physiology.

[37]  J. Werner,et al.  Low‐dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer , 2013, International journal of cancer.

[38]  R. Kaneno,et al.  Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy , 2013, International journal of cancer.

[39]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[40]  Md. Lutful Amin.  P-glycoprotein Inhibition for Optimal Drug Delivery , 2013, Drug target insights.

[41]  F. Hu,et al.  Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation , 2012, International journal of nanomedicine.

[42]  J. Neal,et al.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Schneeweiss,et al.  Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome , 2012, Cancer Immunology, Immunotherapy.

[44]  C. Burd,et al.  Physiology and Pathology of Endosome‐to‐Golgi Retrograde Sorting , 2011, Traffic.

[45]  Amit Kumar,et al.  Unveiling the mechanism of uptake and sub-cellular distribution of cerium oxide nanoparticles. , 2010, Molecular bioSystems.

[46]  E. Proietti,et al.  Combination strategies for enhancing the efficacy of immunotherapy in cancer patients , 2010, Annals of the New York Academy of Sciences.

[47]  A. Coyle,et al.  HMGB1 and RAGE in inflammation and cancer. , 2010, Annual review of immunology.

[48]  J. Pignon,et al.  Immunogenic death of colon cancer cells treated with oxaliplatin , 2010, Oncogene.

[49]  P. Dawson,et al.  Bile acid transporters , 2009, Journal of Lipid Research.

[50]  G. Ubeaud‐Séquier,et al.  Quercetin and naringenin transport across human intestinal Caco‐2 cells , 2009 .

[51]  J. Tschopp,et al.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.

[52]  Michael R. Elliott,et al.  Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance , 2009, Nature.

[53]  H. Matsushima,et al.  Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. , 2009, Cancer research.

[54]  B. Clausen,et al.  Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. , 2009, Cancer research.

[55]  D. Getnet,et al.  Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. , 2009, Cancer research.

[56]  R. Teasdale,et al.  Defining Macropinocytosis , 2009, Traffic.

[57]  C. Chan,et al.  Formulation Development and Bioavailability Evaluation of a Self-Nanoemulsified Drug Delivery System of Oleanolic Acid , 2009, AAPS PharmSciTech.

[58]  N. Russo,et al.  Neutral and acidic hydrolysis reactions of the third generation anticancer drug oxaliplatin. , 2009, The journal of physical chemistry. B.

[59]  Gaurav Sahay,et al.  Different internalization pathways of polymeric micelles and unimers and their effects on vesicular transport. , 2008, Bioconjugate chemistry.

[60]  J. Schlom,et al.  Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement , 2008, Clinical Cancer Research.

[61]  C. Apicella,et al.  Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[62]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[63]  F. Di Virgilio,et al.  Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells , 2007, Nature Medicine.

[64]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[65]  V. Khoo,et al.  Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. , 2007, The Journal of urology.

[66]  B. Chauffert,et al.  Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.

[67]  G. Francini,et al.  A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. , 2006, Oncology reports.

[68]  J. Polli,et al.  Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. , 2006, Molecular pharmaceutics.

[69]  L. Kaiser,et al.  Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.

[70]  Xiaoling Fang,et al.  Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[71]  J. Schlom,et al.  Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.

[72]  L. Benjamin,et al.  Angiogenesis: Tumorigenesis and the angiogenic switch , 2003, Nature Reviews Cancer.

[73]  S. Eksborg,et al.  Hydrolysis of oxaliplatin-evaluation of the acid dissociation constant for the oxalato monodentate complex. , 2003, Journal of pharmaceutical sciences.

[74]  R. Kerbel,et al.  Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. , 2002, Cancer research.

[75]  Peter Bohlen,et al.  Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. , 2002, Cancer research.

[76]  B. Shneider.  Intestinal bile acid transport: biology, physiology, and pathophysiology. , 2001, Journal of pediatric gastroenterology and nutrition.

[77]  G. Sledge,et al.  Redefining the target: chemotherapeutics as antiangiogenics. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  Gabriele Bergers,et al.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.

[79]  Peter Bohlen,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .

[80]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[81]  A. Hofmann,et al.  The continuing importance of bile acids in liver and intestinal disease. , 1999, Archives of internal medicine.

[82]  T. Ono,et al.  Regulation of expression of human intestinal bile acid-binding protein in Caco-2 cells. , 1998, The Biochemical journal.

[83]  J. Lippincott-Schwartz,et al.  Brefeldin A: insights into the control of membrane traffic and organelle structure , 1992, The Journal of cell biology.

[84]  P. Artursson,et al.  Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.

[85]  R. Kumar,et al.  Preparation and characterization of nanoemulsion encapsulating curcumin , 2015 .

[86]  I. D. de Vries,et al.  Molecular Pathways Molecular Pathways : The Immunogenic Effects of Platinum-Based Chemotherapeutics , 2014 .

[87]  T. Lynch,et al.  Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[88]  L. Zitvogel,et al.  Immunological aspects of cancer chemotherapy , 2008, Nature Reviews Immunology.

[89]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.